BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-02: Form 8-K; Period of report 2016-11-28; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
- 2016-11-09: Form 8-K; Period of report 2016-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-11-04: Form 8-K; Period of report 2016-11-04; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2016-10-28: Form 8-K; Period of report 2016-10-28; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-02 | 8-K | 2016-11-28 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | bioc-8k_20161128.htm | |
| 2016-11-09 | 8-K | 2016-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2016, we issued a press release announcing our financial results for the three and nine months ended September 30, 2016. | bioc-8k_20161109.htm |
| 2016-11-04 | 8-K | 2016-11-04 | 1.02 Termination of a Material Definitive Agreement | 1.02 On November 4, 2016, Biocept, Inc. (the “Company”) voluntarily terminated the common stock purchase agreement (the “Purchase Agreement”) that the Company entered into on December 21, 2015, with Aspire Capital Fund, LLC (“Aspire Capital”). | bioc-8k_20161104.htm |
| 2016-10-28 | 8-K | 2016-10-28 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 The disclosure set forth below in Item 8.01 is incorporated herein by reference. 8.01 On May 20, 2016, Biocept, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq has determined that the Company has failed to comply with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). | bioc-8k_20161028.htm |
| 2016-09-29 | 8-K | 2016-09-27 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.03 As discussed below in Item 5.07, Biocept, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) at which the Company’s stockholders approved (i) a proposal to amend the Company’s Certificate of Amendment of Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares and (ii) a proposal to amend the Company’s Certificate of Amendment of Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1:3 to 1:5, such ratio to be determined in the discretion of the Company’s board of directors. 5.07 On September 27, 2016, the Company held the Special Meeting. 8.01 The Company is filing certain information for the purpose of updating the description of the Company’s risk factors contained in its other filings with the Securities and Exchange Commission. | bioc-8k_20160927.htm |
| 2016-08-03 | 8-K | 2016-08-02 | 7.01 Regulation FD Disclosure | 7.01 On August 2, 2016, Biocept, Inc. released a presentation on its corporate website providing a corporate overview. | bioc-8k_20160802.htm |
| 2016-08-02 | 8-K | 2016-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2016, we issued a press release announcing our financial results for the three and six months ended June 30, 2016. | bioc-8k_20160802.htm |
| 2016-08-01 | 8-K | 2016-07-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 · Mr. Foletta will remain a full-time employee of the Company through August 31, 2016, and during such period will be entitled to receive a base salary of $25,000 per month. | bioc-8k_20160729.htm |
| 2016-07-27 | 8-K | 2016-07-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 25, 2016, in connection with the hiring of Timothy Kennedy (as described below), Biocept, Inc. (the “Company”) and Mark G. Foletta mutually agreed that he would resign from his position as the interim Chief Financial Officer of the Company, effective immediately. | d200150d8k.htm |
| 2016-07-07 | 8-K | 2016-07-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Each of these RSUs were granted pursuant to the Company’s Amended and Restated 2013 Equity Incentive Plan. | bioc-8k_20160706.htm |
| 2016-06-29 | 8-K | 2016-06-28 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 28, 2016, Biocept, Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”). | bioc-8k_20160628.htm |
| 2016-06-17 | 8-K | 2016-06-16 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | bioc-8k_20160616.htm | |
| 2016-05-26 | 8-K | 2016-05-20 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 20, 2016, Biocept, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq has determined that the Company has failed to comply with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). | bioc-8k_20160520.htm |
| 2016-05-12 | 8-K | 2016-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2016, we issued a press release announcing our financial results for the three months ended March 31, 2016. | bioc-8k_20160512.htm |
| 2016-04-29 | 8-K | 2016-04-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | bioc-8k_20160429.htm |
| 2016-03-09 | 8-K | 2016-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2016, we issued a press release announcing our financial results for the three months and year ended December 31, 2015. | bioc-8k_20160309.htm |
| 2016-02-26 | 8-K | 2016-02-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 21, 2016, Biocept, Inc. (the “Company”) filed a Registration Statement on Form S-1/A with the Securities and Exchange Commission (the “Registration Statement”). | bioc-8k_20160223.htm |